# Instil Bio, Inc.: financial statements, quarterly

TIL · Nasdaq · CIK 1789769 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/til.md) · [Financials](/companies/til/financials.md) · [Filings](/companies/til/filings.md) · [Insiders](/companies/til/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/til/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [8.5](/filings/0001789769-23-000093.md) | [2.0 d](/filings/0001789769-24-000036.md) | [7.3](/filings/0001789769-24-000059.md) | [2.9](/filings/0001789769-24-000086.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(66.7)](/filings/0001789769-24-000103.md) | [(13.0) d](/filings/0001789769-25-000017.md) | [(24.0)](/filings/0001789769-25-000051.md) | [(14.1)](/filings/0001789769-25-000081.md) | [(23.6)](/filings/0001789769-25-000094.md) | [(11.8) d](/filings/0001789769-26-000019.md) | [(30.6)](/filings/0001789769-26-000045.md) | [(23.4)](/filings/0001789769-26-000057.md) | [(15.0)](/filings/0001789769-25-000094.md) | [(9.6) d](/filings/0001789769-26-000019.md) | [(7.0)](/filings/0001789769-26-000045.md) | [(5.6)](/filings/0001789769-26-000057.md) |
| Interest expense | $m | [2.0](/filings/0001789769-23-000093.md) | [2.0 d](/filings/0001789769-24-000036.md) | [2.0](/filings/0001789769-24-000059.md) | [2.0](/filings/0001789769-25-000081.md) | [2.0](/filings/0001789769-25-000094.md) | [3.0 d](/filings/0001789769-26-000019.md) | [1.1](/filings/0001789769-26-000045.md) | [1.6](/filings/0001789769-26-000057.md) | [1.6](/filings/0001789769-25-000094.md) | [1.6 d](/filings/0001789769-26-000019.md) | [1.6](/filings/0001789769-26-000045.md) | [1.6](/filings/0001789769-26-000057.md) |
| Income tax | $m | [0.0](/filings/0001789769-23-000093.md) | [0.0 d](/filings/0001789769-24-000036.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(67.4)](/filings/0001789769-24-000103.md) | [(12.9) d](/filings/0001789769-25-000017.md) | [(24.3)](/filings/0001789769-25-000094.md) | [(14.9)](/filings/0001789769-25-000094.md) | [(23.0)](/filings/0001789769-25-000094.md) | [(11.9) d](/filings/0001789769-26-000019.md) | [(28.2)](/filings/0001789769-26-000057.md) | [(21.4)](/filings/0001789769-26-000057.md) | [(13.6)](/filings/0001789769-25-000094.md) | [(8.2) d](/filings/0001789769-26-000019.md) | [(4.2)](/filings/0001789769-26-000057.md) | [(4.3)](/filings/0001789769-26-000057.md) |
| Diluted EPS | $ per share | [(10.37)](/filings/0001789769-24-000103.md) | not reported | [(3.74)](/filings/0001789769-25-000051.md) | [(2.29)](/filings/0001789769-25-000081.md) | [(3.54)](/filings/0001789769-25-000094.md) | not reported | [(4.32)](/filings/0001789769-26-000045.md) | [(3.24)](/filings/0001789769-26-000057.md) | [(2.01)](/filings/0001789769-25-000094.md) | not reported | [(0.62)](/filings/0001789769-26-000045.md) | [(0.63)](/filings/0001789769-26-000057.md) |
| Basic EPS | $ per share | [(10.37)](/filings/0001789769-24-000103.md) | not reported | [(3.74)](/filings/0001789769-25-000051.md) | [(2.29)](/filings/0001789769-25-000081.md) | [(3.54)](/filings/0001789769-25-000094.md) | not reported | [(4.32)](/filings/0001789769-26-000045.md) | [(3.24)](/filings/0001789769-26-000057.md) | [(2.01)](/filings/0001789769-25-000094.md) | not reported | [(0.62)](/filings/0001789769-26-000045.md) | [(0.63)](/filings/0001789769-26-000057.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.1](/filings/0001789769-23-000093.md) | [9.2](/filings/0001789769-25-000017.md) | [5.5](/filings/0001789769-24-000059.md) | [6.8](/filings/0001789769-24-000086.md) | [6.7](/filings/0001789769-24-000103.md) | [8.8](/filings/0001789769-26-000019.md) | [15.4](/filings/0001789769-25-000051.md) | [7.7](/filings/0001789769-25-000081.md) | [5.8](/filings/0001789769-25-000094.md) | [6.6](/filings/0001789769-26-000057.md) | [5.0](/filings/0001789769-26-000045.md) | [5.5](/filings/0001789769-26-000057.md) |
| Current assets | $m | [196](/filings/0001789769-23-000093.md) | [161](/filings/0001789769-25-000017.md) | [161](/filings/0001789769-24-000059.md) | [155](/filings/0001789769-24-000086.md) | [133](/filings/0001789769-24-000103.md) | [124](/filings/0001789769-26-000019.md) | [219](/filings/0001789769-25-000051.md) | [207](/filings/0001789769-25-000081.md) | [196](/filings/0001789769-25-000094.md) | [191](/filings/0001789769-26-000057.md) | [188](/filings/0001789769-26-000045.md) | [71.6](/filings/0001789769-26-000057.md) |
| Total assets | $m | [340](/filings/0001789769-23-000093.md) | [326](/filings/0001789769-25-000017.md) | [306](/filings/0001789769-24-000059.md) | [294](/filings/0001789769-24-000086.md) | [273](/filings/0001789769-24-000103.md) | [264](/filings/0001789769-26-000019.md) | [237](/filings/0001789769-25-000051.md) | [231](/filings/0001789769-25-000081.md) | [212](/filings/0001789769-25-000094.md) | [204](/filings/0001789769-26-000057.md) | [200](/filings/0001789769-26-000045.md) | [198](/filings/0001789769-26-000057.md) |
| Current liabilities | $m | [13.5](/filings/0001789769-23-000093.md) | [10.6](/filings/0001789769-25-000017.md) | [11.4](/filings/0001789769-24-000059.md) | [10.3](/filings/0001789769-24-000086.md) | [10.3](/filings/0001789769-24-000103.md) | [7.9](/filings/0001789769-26-000019.md) | [7.2](/filings/0001789769-25-000051.md) | [13.9](/filings/0001789769-25-000081.md) | [5.7](/filings/0001789769-25-000094.md) | [4.8](/filings/0001789769-26-000057.md) | [4.7](/filings/0001789769-26-000045.md) | [3.3](/filings/0001789769-26-000057.md) |
| Total liabilities | $m | [106](/filings/0001789769-23-000093.md) | [99.8](/filings/0001789769-25-000017.md) | [100](/filings/0001789769-24-000059.md) | [99.3](/filings/0001789769-24-000086.md) | [96.2](/filings/0001789769-24-000103.md) | [94.1](/filings/0001789769-26-000019.md) | [92.5](/filings/0001789769-25-000051.md) | [99.3](/filings/0001789769-25-000081.md) | [91.3](/filings/0001789769-25-000094.md) | [89.7](/filings/0001789769-26-000057.md) | [89.7](/filings/0001789769-26-000045.md) | [90.3](/filings/0001789769-26-000057.md) |
| Shareholders' equity | $m | [234](/filings/0001789769-24-000103.md) | [226](/filings/0001789769-26-000019.md) | [206](/filings/0001789769-25-000094.md) | [195](/filings/0001789769-25-000094.md) | [176](/filings/0001789769-25-000094.md) | [169](/filings/0001789769-26-000057.md) | [145](/filings/0001789769-26-000057.md) | [132](/filings/0001789769-26-000057.md) | [120](/filings/0001789769-25-000094.md) | [114](/filings/0001789769-26-000057.md) | [111](/filings/0001789769-26-000057.md) | [107](/filings/0001789769-26-000057.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.4) d](/filings/0001789769-24-000103.md) | [(13.4) d](/filings/0001789769-25-000017.md) | [(14.4)](/filings/0001789769-25-000051.md) | [(10.6) d](/filings/0001789769-25-000081.md) | [(20.1) d](/filings/0001789769-25-000094.md) | [(10.6) d](/filings/0001789769-26-000019.md) | [(4.2)](/filings/0001789769-26-000045.md) | [(14.8) d](/filings/0001789769-26-000057.md) | [(10.6) d](/filings/0001789769-25-000094.md) | [(7.1) d](/filings/0001789769-26-000019.md) | [(1.3)](/filings/0001789769-26-000045.md) | [(4.6) d](/filings/0001789769-26-000057.md) |
| Capital expenditure | $m | [5.2 d](/filings/0001789769-24-000103.md) | [0.1 d](/filings/0001789769-25-000017.md) | [0.0](/filings/0001789769-24-000059.md) | [0.0 d](/filings/0001789769-24-000086.md) | [0.0 d](/filings/0001789769-24-000103.md) | [0.0 d](/filings/0001789769-25-000017.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [130](/filings/0001789769-23-000093.md) | [6.5](/filings/0001789769-24-000059.md) | [6.5](/filings/0001789769-24-000086.md) | [6.5](/filings/0001789769-24-000103.md) | [6.5](/filings/0001789769-25-000051.md) | [6.5](/filings/0001789769-25-000081.md) | [6.5](/filings/0001789769-25-000094.md) | [6.5](/filings/0001789769-26-000045.md) | [6.6](/filings/0001789769-26-000057.md) | [6.8](/filings/0001789769-25-000094.md) | [6.8](/filings/0001789769-26-000045.md) | [6.8](/filings/0001789769-26-000057.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,781,976 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001789769-26-000057.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.